Specialized Therapies | HIV and Oncology
Press Releases and Company Announcements
Open Letter to Shareholders from CEO Paul Levesque
Theratechnologies Announces Update from Ongoing TH1902 Study
Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
Theratechnologies develops and commercializes innovative therapies. We have a Phase 1 clinical trial in oncology using our novel and proprietary SORT1+ Technology™. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for nonalcoholic steatohepatitis (NASH), a severe liver condition which affects a growing number of people around the world.
Making a difference through innovation
Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs.